On Monday, shares of Juniper Networks, Inc. (NYSE:JNPR), included 0.04% and shut at $26.36 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $26.09 and $26.60. Juniper Networks (JNPR), an industry leader in automated, scalable and secure networks, recently declared the Company will present at the following shareholder conferences in December:
Mike Marcellin, Senior Vice President and Chief Marketing Officer at Juniper Networks, will present at the Raymond James Technology Shareholders Conference, Tuesday, December 6th, 2016 at 9:35am, ET in New York City.
Ken Miller, Chief Financial Officer at Juniper Networks, will present at the Barclays Global Technology, Media and Telecommunications Conference, Wednesday, December 7th, 2016 at 9am, PT in San Francisco.
Shares of Amgen, Inc. (NASDAQ:AMGN), added 0.22% and shut at $145.55 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $145.11 and $146.17. The association’s commercial center capitalization is $106.71 Billion with the general uncommon loads of 743.92 million. Amgen (AMGN) recently declared positive top-line results for erenumab from a global Phase 3, randomized, double-blind, placebo-controlled STudy to evaluate the efficacy and safety of erenumab in migRaIne preVEntion (STRIVE). These data showed the STRIVE study met the primary endpoint, demonstrating statistically noteworthyreductions from baseline in monthly migraine days in patients with episodic migraine treated with either 70 mg or 140 mg erenumab contrast with placebo. Erenumab is specifically designed to prevent migraine by blocking the Calcitonin Gene-Related Peptide (CGRP) receptor, which is believed to have a critical role in mediating the incapacitating pain of migraine.
“Migraine is ranked one of the most debilitating diseases by the World Health Organization, yet it is often under-diagnosed and under-treated. People who experience migraine battle the disease for many years and it has noteworthyimpact on their everyday activities,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “The results of this study are important because they confirm the results from our previous studies and add to our body of research in episodic migraine. We look forward to working with regulatory authorities to pursue approval of erenumab and making this novel migraine prevention treatment available to patients and physicians.”